Literature DB >> 2837141

Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.

N J Robillard1, A L Scarpa.   

Abstract

Spontaneous ciprofloxacin-resistant mutants of Pseudomonas aeruginosa PAO2 were isolated on ML agar containing 0.5 microgram of ciprofloxacin per ml (2 times the MIC). The mutants were 8- to 64-fold more resistant to ciprofloxacin and showed complete cross resistance to nalidixic acid, ofloxacin, enoxacin, and norfloxacin. Two chromosomal resistance genes, cfxA and cfxB, were mapped between eda-9001 and phe-2 and near pyrB52 distal to proC130, respectively. The cfxB mutation was identical to a nalB mutation and conferred cross resistance to novobiocin, tetracycline, carbenicillin, and chloramphenicol, suggesting that there is an effect on permeability. DNA gyrase A and B subunits were purified from strain PAO2 (wild type), PAO236 nalA2, PAO4704 cfxA2, and PAO4700 cfxA1 cfxB1. Inhibition of gyrase-mediated DNA supercoiling by ciprofloxacin or nalidixic acid was greatly reduced in preparations derived from each of the mutants. Inhibition studies on reconstituted heterologous gyrase subunits showed that decreased inhibition was dependent on the mutant gyrase A subunit. We conclude that ciprofloxacin resistance in P. aeruginosa PAO2 can occur by mutation in the nalB gene or the gene for DNA gyrase A (formerly nalA).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837141      PMCID: PMC172216          DOI: 10.1128/AAC.32.4.535

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Cloning and simplified purification of Escherichia coli DNA gyrase A and B proteins.

Authors:  K Mizuuchi; M Mizuuchi; M H O'Dea; M Gellert
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

Review 2.  DNA topoisomerases.

Authors:  M Gellert
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

3.  Pseudomonas aeruginosa outer membrane permeability: isolation of a porin protein F-deficient mutant.

Authors:  T I Nicas; R E Hancock
Journal:  J Bacteriol       Date:  1983-01       Impact factor: 3.490

4.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.

Authors:  M Rella; D Haas
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

6.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

7.  Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes.

Authors:  F Yoshimura; H Nikaido
Journal:  J Bacteriol       Date:  1982-11       Impact factor: 3.490

8.  Chromosomal mapping of mutations affecting glycerol and glucose catabolism in Pseudomonas aeruginosa PAO.

Authors:  S M Cuskey; P V Phibbs
Journal:  J Bacteriol       Date:  1985-06       Impact factor: 3.490

9.  Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant.

Authors:  B L Angus; A M Carey; D A Caron; A M Kropinski; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

10.  DNA gyrase: affinity chromatography on novobiocin-Sepharose and catalytic properties.

Authors:  W L Staudenbauer; E Orr
Journal:  Nucleic Acids Res       Date:  1981-08-11       Impact factor: 16.971

View more
  49 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 2.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

3.  A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.

Authors:  L J Piddock; M C Hall; F Bellido; M Bains; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

Authors:  R R Muder; C Brennen; A M Goetz; M M Wagener; J D Rihs
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 5.  Structure-activity relationships of the fluoroquinolones.

Authors:  D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

6.  Resistance to pefloxacin in Pseudomonas aeruginosa.

Authors:  M Michea-Hamzehpour; C Lucain; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

7.  Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.

Authors:  B L Masecar; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

8.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa.

Authors:  R A Celesk; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 10.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.